The STem cells for ARDS Treatment (START) trial showed that MSC treatment significantly reduced the concentrations of angiopoietin-2 (Ang-2) in the airspace compared to the placebo. This evidence concerns the gene ANGPT2 and acute respiratory distress syndrome.